Day: August 9, 2022

ACTengine® TCR-T cell therapy targeting PRAME is enrolling patients in all three Phase 1b cohorts: IMA203 monotherapy at provisional recommended Phase 2 dose (RP2D) (Cohort A), IMA203/nivolumab checkpoint inhibitor combination (Cohort B) and IMA203CD8 2nd generation monotherapy (Cohort C)TCR Bispecific candidate TCER® IMA401 targeting MAGEA4/A8 Phase 1a clinical trial initiated in patients with recurrent and/or refractory solid tumorsNew multi-program collaboration initiated with Bristol Myers Squibb to develop allogeneic TCR-T/CAR-T programs using Immatics’ proprietary ACTallo® platform; Immatics received $60 million upfront payment and is eligible for up to $700 million per program in milestone payments as well as tiered royaltiesAutologous TCR-T collaboration with Bristol Myers Squibb from 2019 expanded to include one additional...

CHICAGO, Aug. 09, 2022 (GLOBE NEWSWIRE) — Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI) (“Chicago Atlantic” or the “Company”), a commercial real estate finance company, today announced its results for the second quarter ended June 30, 2022. John Mazarakis, Executive Chairman of Chicago Atlantic, noted, “The cannabis market fundamentals across the country continue to demonstrate that our strategy of lending to borrowers in limited-license states primarily with vertically integrated operations has created a strong investment platform and a very valuable loan portfolio. In order to protect book value while remaining conservatively levered, we have elected to limit additional growth in the REIT portfolio that would require funding from a dilutive equity or debt offering and rather meet the strong demand in our large loan...

HeadlinesDelivered strong performance in core automotive business Achieved record professional services revenue, a key indicator of license and connected services growth Secured key wins and nominations including a win back from Big Tech Maintained strong focus on productivity, performance-based operations and cost structures Economics, predictability, and visibility will be enhanced by returning to historical levels of fixed contractsBURLINGTON, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) — Cerence Inc. (NASDAQ: CRNC), AI for a world in motion, today reported its third quarter fiscal year 2022 results for the quarter ended June 30, 2022. Results Summary (1)(in millions, except per share data)    Three Months Ended   Nine Months Ended    June 30,   June 30,    2022   2021   2022   2021GAAP Revenue   $ 89.0     $ 96.8     $ 269.7     $ 289.1  GAAP...

Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022 Phase 3 ROMAN trial data highlighted in an oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Phase 1 stage of GRECO-1 trial demonstrated rucosopasem in combination with SBRT was well tolerated with early indications of anti-cancer activity Completion of enrollment in both GRECO-1 and GRECO-2 trials of rucosopasem in combination with SBRT expected in 2H 2023 MALVERN, Pa., Aug. 09, 2022 (GLOBE NEWSWIRE) — Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the second quarter ended June 30, 2022 and provided...

Second Quarter 2022 Revenue Growth of 29.0%; Organic Constant Currency Revenue Growth of 22.8% Increasing Full Year 2022 Guidance to Reflect Strong Second Quarter and Improved Outlook NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) — Sterling Check Corp. (NASDAQ: STER) (“Sterling” or “the Company”) a leading global provider of technology-enabled background and identity verification services, today announced financial results for the second quarter ended June 30, 2022. Second Quarter 2022 Highlights All results compared to prior-year period.Revenues increased 29.0% year-over-year to $205.6 million. Organic constant currency revenue growth was 22.8% and inorganic revenue growth was 7.7%.GAAP net income increased year-over-year to $11.6 million, or $0.12 per diluted share, compared to GAAP net income of $3.4 million, or $0.04 per diluted...

Initiated dosing in patient cohort (Part C) of IRAK4 degrader KT-474 Phase 1 trial, on track for data by year end Phase 1 patient studies initiated for STAT3 (KT-333) and IRAKIMiD (KT-413) oncology programs,initial data to be shared by year end June 30, 2022 cash balance of $482.5 million, providing cash runway into 2025 Company to hold quarterly results call at 8:30 a.m. EST (877-317-6789 or +1 412-317-6789) WATERTOWN, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today reported business highlights and financial results for the second quarter ended June 30, 2022. “Kymera has made strong progress, dosing patients in our three first-in-class clinical programs...

Delivered $55.8 Million of Revenue, Above High End of Guidance Range Generated 37.5% Gross Margin, Above High End of Guidance Range; Expanded Gross Margin 374 Basis Points Year-over-Year in the First Half of 2022 Generated $7.9 Million of Cash Flow from Operations and $5.4 Million of Free Cash Flow; Repurchased $3.0 Million of Stock Updates 2022 Full Year GuidanceASHBURN, Va., Aug. 09, 2022 (GLOBE NEWSWIRE) — Telos Corporation (NASDAQ: TLS), a leading provider of cyber, cloud and enterprise security solutions for the world’s most security-conscious organizations, today announced financial results for the second quarter 2022. “We executed well in the second quarter, delivering $55.8 million of revenue, above the high end of our guidance range,” said John B. Wood, chairman and CEO, Telos. “We expanded gross margin 374 basis points...

Revenue of $55.5 million, operating profit $1.5 million and Adjusted EBITDA of $5.3 million; Reiterates 2022 guidance PETAH TIKVA, Israel, Aug. 09, 2022 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, today reported its results for the second quarter ended June 30, 2022. Second Quarter 2022 Financial HighlightsRevenues of $55.5 million,up 1.2% compared with Q2 of last year;GAAP operating income of $1.5 million versus operating loss of $0.4 million in Q2 last year;Non-GAAP operating income of $2.4 million versus Non-GAAP operating income of $0.1 million in Q2 last year;GAAP net income of $0.5 million versus loss of $0.2 million in Q2 last year;Non-GAAP net income of $1.4 million versus Non-GAAP income of $0.3 million...